Subscribe to Search results

Carol Grayson wrote to Frank Dobson to enquire about plans to roll out recombinant to all patients, but was told in reply that "there are no plans to arrange this centrally" and that "the Department of Health does not accept that the clinical case has been made for the general use of the recombinant product".

Published on:

One man wrote to Tony Blair expressing his concern that his son's haemophilia treatment might revert to human-derived plasma after he reached the age threshold, as well as expressing further concerns about the affordability of recombinant Factor 8.

Published on:

A Health Services Circular (HSC 1998/999) was published. This promulgated the announcement that central funding would be provided to health authorities in order to provide recombinant Factor 8 to new patients as well as patients under the age of 16.

Published on:

The Department of Health published a further Health Services Circular (HSC 1998/147). This document considered specific arrangements for health authorities to submit claims for additional funding to provide recombinant Factor 8.

Published on:

The Secretary of State agreed to the central funding for 1998/1999 of recombinant Factor VIII for new patients and those under 16. This was on what were described as humanitarian (rather than effectiveness grounds).

Published on:

At a meeting of the UKHCDO Executive Committee Dr Ludlam said that Charles Lister had "again informally indicated that funding for [Factor 8] should continue beyond the 16th birthday."

Published on:

Bruce Norval described writing to the Secretary of State "to try and make sure that kids got on to recombinant products as early as possible".

Published on:

Pete Longstaff refused human derived Factor 8 products in a treatment strike which lasted until his death.

Published on:

Recombinant Factor 9 was licensed and the funding arrangements in England mirrored those for Factor 8.

Published on:

Charles Lister wrote to Nick Raisen regarding synthetic blood products.

Published on:

By this date all patients with Haemophilia in Scotland were being treated with recombinant Factor 8 or 9.

Published on:

By this date it had been confirmed that in Northern Ireland recombinant Factor 8 would be funded for all patients.

Published on:

Individuals were still experiencing issues with equal access to recombinant Factor 8 as a result of funding.

Published on:

It was not until the financial year 2004/2005 that all patients with Haemophilia A, of whatever age, had access to recombinant Factor 8.

Published on:

Judith Paget explained children in Wales can receive recombinant von Willebrand Factor off-label for on-demand treatment of non-surgical and surgical bleeding episodes.

Published on:

Caroline Lamb explained children in Scotland can receive recombinant von Willebrand Factor if appropriate.

Published on:

In Northern Ireland, access to recombinant blood products for children with von Willebrand disorder is available in exceptional cases through the Individual Funding Request ("IFR") route, however to date no IFR has been made.

Published on:

Daniel Eve explained NHS England funded off-label usage of recombinant blood products for post-pubertal children with Von Willebrand Disease. NHS England is in the early stages of considering the possibility of off-label usage for patients under 12.

Published on:

An article on the variation in Hepatitis C services in the UK was published, which found that the majority of patients were not receiving antiviral treatment, in contrast with practice in Europe.

Published on:

Clinical guidelines on the management of hepatitis C were published.

Published on: